alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl-(1->3)-[beta-D-galactosyl-(1->4)-(alpha-L-fucosyl-(1->3))-N-acetyl-beta-D-glucosaminyl-(1->6)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-ceramide(1-)

Term ID

CHEBI:142562

Synonyms

alpha-NeuNAc-(2->3)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-beta-D-GlcNAc-(1->3)-[(beta-D-Gal-(1->4)-alpha-L-Fuc-(1->3))beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(1-)
II(6)gAL(Fuc)GlcNAc-sLe(a)(1-)
lacto II(6)Gal(Fuc)GlcNAc,III(4)Fuc,IV(3)-a-NeuNAc-Lc4Cer
sLea-nonasaccharide(1-)

Definition

References

PMID:8253783

Ontology

ChEBI ( EBI )

Relationships

is a type of: fucosyl oligoglycosylceramide organic molecular entity

fucosyl oligoglycosylceramide organic molecular entity Show first 5 Terms
has subtype: alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-(1->3)-[beta-D-galactosyl-(1->4)-(alpha-L-fucosyl-(1->3))-N-acetyl-beta-D-glucosaminyl-(1->6)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-ceramide(t18:0)(1-)

alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-(1->3)-[beta-D-galactosyl-(1->4)-(alpha-L-fucosyl-(1->3))-N-acetyl-beta-D-glucosaminyl-(1->6)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-ceramide(t18:0)(1-) Show first 5 Terms

Phenotype

Phenotype resulting from alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl-(1->3)-[beta-D-galactosyl-(1->4)-(alpha-L-fucosyl-(1->3))-N-acetyl-beta-D-glucosaminyl-(1->6)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-ceramide(1-)

Phenotype where environments contain alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl-(1->3)-[beta-D-galactosyl-(1->4)-(alpha-L-fucosyl-(1->3))-N-acetyl-beta-D-glucosaminyl-(1->6)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-ceramide(1-)

Phenotype modified by environments containing alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl-(1->3)-[beta-D-galactosyl-(1->4)-(alpha-L-fucosyl-(1->3))-N-acetyl-beta-D-glucosaminyl-(1->6)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-ceramide(1-)

Human Disease Model